Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.66 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.57 |
| ▸ | GAA | P10253 | 2/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14810278 | 0.91 | CHRM1 (0.61) | MAPTALDH1A1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL21411461 | 0.89 | ALDH1A1 (0.62) | MAPTALDH1A1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL7427079 | 0.89 | ALDH1A1 (0.58) | MAPTALDH1A1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL14127719 | 0.89 | MAPT (0.56) | MAPTALDH1A1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL1720494 | 0.87 | MAPT (0.72) | MAPTALDH1A1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL28037969 | 0.85 | CHRM1 (0.56) | MAPTALDH1A1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL5885563 | 0.85 | MAPT (0.70) | MAPTALDH1A1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL2794847 | 0.84 | MAPT (0.51) | MAPTALDH1A1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL13733825 | 0.84 | MAPT (0.51) | MAPTALDH1A1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL16809642 | 0.84 | MAPT (0.68) | MAPTALDH1A1CYP3A4CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4017855-A1 | PYRAZOLO[3,4-B]PYRAZINE SHP2 PHOSPHATASE INHIBITORS | Otsuka Pharmaceutical Co., Ltd. (JP) | 2022-06-29 | — | — | EP | disclosed |
| EP-3947367-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS | Array Biopharma, Inc. (US) | 2022-02-09 | — | — | EP | disclosed |
| EP-3856744-A1 | MANUFACTURE OF COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2 | Novartis AG (CH) | 2021-08-04 | — | — | EP | disclosed |
| WO-2021127337-A1 | TRPML MODULATORS | CASMA THERAPEUTICS, INC. (US) | 2021-06-24 | — | — | WO | disclosed |
| EP-3806855-A1 | GLP-1 RECEPTOR AGONISTS AND USES THEREOF | Pfizer Inc. (US) | 2021-04-21 | — | — | EP | disclosed |
| US-10961225-B2 | Bicyclic AZA compounds as muscarinic M1 receptor and/or M4 receptor | HEPTARES THERAPEUTICS LIMITED (GB) | 2021-03-30 | — | — | US | disclosed |
| WO-2021033153-A1 | PYRAZOLO[3,4-B]PYRAZINE SHP2 PHOSPHATASE INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2021-02-25 | — | — | WO | disclosed |
| EP-3774805-A1 | HETEROBICYCLIC INHIBITORS OF MAT2A AND METHODS OF USE FOR TREATING CANCER | Agios Pharmaceuticals, Inc. (US) | 2021-02-17 | — | — | EP | disclosed |
| US-20200325118-A1 | BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 RECEPTOR AND/OR M4 RECEPTOR | NXERA PHARMA UK LIMITED (GB) | 2020-10-15 | — | — | US | disclosed |
| WO-2020201991-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2020-10-08 | — | — | WO | disclosed |
| EP-2280008-B1 | HETEROCYCLIC-SUBSTITUTED PIPERIDINES AS ORL-1 LIGANDS | PURDUE PHARMA LP (US) | 2013-05-29 | — | — | EP | disclosed |
| WO-2012041872-A1 | N-HETEROARYL COMPOUNDS WITH CYCLIC BRIDGING UNIT FOR THE TREATMENT OF PARASITIC DISEASES | INTERVET INTERNATIONAL B.V. (NL) | 2012-04-05 | — | — | WO | disclosed |
| EP-2397477-A1 | Heterocyclic-substituted piperidine compounds and the uses thereof | Purdue Pharma LP (US) | 2011-12-21 | — | — | EP | disclosed |
| EP-2280008-A2 | Heterocyclic-substituted piperidines as ORL-1 ligands | Purdue Pharma L.P. (US) | 2011-02-02 | — | — | EP | disclosed |
| EP-1789404-B1 | SUBSTITUTED N-ARYLSULFONYLHETEROCYCLIC AMINES AS GAMMA-SECRETASE INHIBITORS | SCHERING CORP (US) | 2010-03-24 | — | — | EP | disclosed |
| WO-2010028254-A2 | SUBSTITUTED QUINAZOLINE INHIBITORS OF GROWTH FACTOR RECEPTOR TYROSINE KINASES | AUSPEK PHARMACEUTICALS, INC. (US) | 2010-03-11 | — | — | WO | disclosed |
| EP-2049124-A2 | PHOSPHORUS DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | Merck & Co., Inc. (US) | 2009-04-22 | — | — | EP | disclosed |
| WO-2008010985-A2 | PHOSPHORUS DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | MERCK & CO., INC. (US) | 2008-01-24 | — | — | WO | disclosed |
| EP-1735313-A1 | SUBSTITUTED DIAZA-SPIRO-[4.5|-DECANE DERIVATIVES AND THEIR USE AS NEUROKININ ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-12-27 | — | — | EP | disclosed |
| WO-2005097794-A1 | SUBSTITUTED DIAZA-SPIRO-[4.5]-DECANE DERIVATIVES AND THEIR USE AS NEUROKININ ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200325118-A1 | BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 RECEPTOR AND/OR M4 RECEPTOR | CHRM1, CHRM2, CHRM4 | MAPT 3528/4885ALDH1A1 1306/4885CYP3A4 389/4885 |
| US-10961225-B2 | Bicyclic AZA compounds as muscarinic M1 receptor and/or M4 receptor | CHRM1, CHRM2, CHRM4 | MAPT 3528/4885ALDH1A1 1306/4885CYP3A4 389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.